Mahkam Zanganeh

Mahkam Zanganeh

Co-Chief Executive Officer, President and DirectoratSummit Therapeutics· In proxies 2021–2025

Pay in FY2024-94% from the year before · Summit Therapeutics stock +583.7% the same year

Mahkam Zanganeh was paid $1.2M in FY2024 (Dec), down 94%. Summit Therapeutics stock rose 583.7% that year.

Pay$100 in the stock at the end of FY20 → $380
Pay is from the Summary Compensation Table of each Summit Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Summit TherapeuticsPublic company · 5 yr
    • Co-Chief Executive Officer, President and Director2021 – Present · 5 yrStock in role +177%
  2. Pulse Biosciences, Inc.Public company · 9 yr
    • Director2017 – Present · 9 yrNo stock prices for these years
  3. RenovoRXPublic company · 3 yr
    • Director2018 – 2021 · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Summit TherapeuticsDirector · 3 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?